Women's Health
Sacituzumab Govitecan Moves Into First-Line TNBC Care
The FDA approved first-line sacituzumab govitecan alone for patients unable to receive checkpoint inhibition and with pembrolizumab for PD-L1–positive advanced triple-negative breast cancer.
Rayan Salih · September 22, 2026 · 7 min